Cargando…
Drug repurposing for SARS-CoV-2 (COVID-19) treatment
Drug repurposing involves the process of investigating already existing drugs with an aim to use them for different therapeutic purposes than the intended one. This approach is relatively faster, less costly, and reliable in terms of safety as the drug under study is already derisked and known for i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217734/ http://dx.doi.org/10.1016/B978-0-323-85156-5.00027-4 |
_version_ | 1784731718758957056 |
---|---|
author | Mtewa, Andrew G. Amanjot, Annu Yadesa, Tadele Mekuriya Ngwira, Kennedy J. |
author_facet | Mtewa, Andrew G. Amanjot, Annu Yadesa, Tadele Mekuriya Ngwira, Kennedy J. |
author_sort | Mtewa, Andrew G. |
collection | PubMed |
description | Drug repurposing involves the process of investigating already existing drugs with an aim to use them for different therapeutic purposes than the intended one. This approach is relatively faster, less costly, and reliable in terms of safety as the drug under study is already derisked and known for its other chemistry and pharmacokinetic properties. With these benefits in mind, it is a very reliable way to undertake drug development for emerging diseases such as COVID-19 which demand immediate interventions to slow or completely stop its havoc on mankind. One of the biggest challenges that drug repurposing has is the possibility of the occurrence of new mechanisms of action between the drug ligand and some proteins in the human physiology. Drug repurposing appears to have settled in the meantime in drug development, though more studies in the future will be warranted particularly in regards to resistance. |
format | Online Article Text |
id | pubmed-9217734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-92177342022-06-23 Drug repurposing for SARS-CoV-2 (COVID-19) treatment Mtewa, Andrew G. Amanjot, Annu Yadesa, Tadele Mekuriya Ngwira, Kennedy J. Coronavirus Drug Discovery Article Drug repurposing involves the process of investigating already existing drugs with an aim to use them for different therapeutic purposes than the intended one. This approach is relatively faster, less costly, and reliable in terms of safety as the drug under study is already derisked and known for its other chemistry and pharmacokinetic properties. With these benefits in mind, it is a very reliable way to undertake drug development for emerging diseases such as COVID-19 which demand immediate interventions to slow or completely stop its havoc on mankind. One of the biggest challenges that drug repurposing has is the possibility of the occurrence of new mechanisms of action between the drug ligand and some proteins in the human physiology. Drug repurposing appears to have settled in the meantime in drug development, though more studies in the future will be warranted particularly in regards to resistance. 2022 2022-06-10 /pmc/articles/PMC9217734/ http://dx.doi.org/10.1016/B978-0-323-85156-5.00027-4 Text en Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Mtewa, Andrew G. Amanjot, Annu Yadesa, Tadele Mekuriya Ngwira, Kennedy J. Drug repurposing for SARS-CoV-2 (COVID-19) treatment |
title | Drug repurposing for SARS-CoV-2 (COVID-19) treatment |
title_full | Drug repurposing for SARS-CoV-2 (COVID-19) treatment |
title_fullStr | Drug repurposing for SARS-CoV-2 (COVID-19) treatment |
title_full_unstemmed | Drug repurposing for SARS-CoV-2 (COVID-19) treatment |
title_short | Drug repurposing for SARS-CoV-2 (COVID-19) treatment |
title_sort | drug repurposing for sars-cov-2 (covid-19) treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217734/ http://dx.doi.org/10.1016/B978-0-323-85156-5.00027-4 |
work_keys_str_mv | AT mtewaandrewg drugrepurposingforsarscov2covid19treatment AT amanjotannu drugrepurposingforsarscov2covid19treatment AT yadesatadelemekuriya drugrepurposingforsarscov2covid19treatment AT ngwirakennedyj drugrepurposingforsarscov2covid19treatment |